Laboratorios Lesvi S.L.

7 trials 1 recruiting Commercial sponsor Merged from 4 name variants

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

5 Completed trials

2 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase IV

Phase I (Other)

Other

Phase III: 1 Phase IV: 1 Phase I (Other): 2 Other: 3

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Anxiety 2 Delirium tremens 2 Eye inflammation 1 Dry eye 1 Meibomian gland dysfunction 1 Chronic obstructive pulmonary disease 1 Eye pain 1

Top IMPs

OXAZEPAM 2 CLOBETASOL PROPIONATE 1 HYDROCORTISONE SODIUM PHOSPHATE 1 MIDAZOLAM 1 PREDNISOLONE ACETATE 1

All trials

7 total

An Open Label Study to Assess the Effect of Patient Use and Robustness on Tiotropium Bromide Spray 2.5μg, Soft Mist Inhaler device Pending

2025-522412-16-00 Phase I (Other) 1 country
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic n… Recruiting

2024-513489-20-00 Phase III 1 country CLOBETASOL PROPIONATE; PREDNISOLONE ACETATE
Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate. Ended

2025-524102-15-00 Phase I (Other) 1 country
Comparative Bioavailability of Midazolam 7.5 mg/1.5 mL Oromucosal Solution (Buccolam®) Versus 10 mg/2 mL Solution for Injection (Hypnovel®) … Ended

2023-504903-10-00 1 country MIDAZOLAM
Bioequivalence of Oxazepam 50 mg Orodispersible Tablets Versus Seresta® 50 mg Tablets in Healthy Subjects. Ended

2022-501135-16-00 1 country OXAZEPAM
Bioequivalence of Oxazepam 10 mg Orodispersible Tablets Versus Seresta® 10 mg Tablets in Healthy Subjects Ended

2022-501134-35-00 1 country OXAZEPAM
Evaluation of the efficacy and safety of topical treatment on clinical signs and symptoms of dry eye disease associated with moderate meibom… Ended

2024-518093-13-00 Phase IV 1 country HYDROCORTISONE SODIUM PHOSPHATE

Showing 1–7 of 7 trials

← All sponsors A–Z